Results 71 to 80 of about 38,007 (143)

Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-"Yes". [PDF]

Mult Scler, 2022
Rolfes L, Meuth SG.
europepmc   +1 more source

Natalizumab extended-interval dosing in multiple sclerosis to mitigate progressive multifocal leukoencephalopathy risk: initial study evidence and real-world experience. [PDF]

J Cent Nerv Syst Dis, 2022
Perncezky J, Sellner J.
europepmc   +1 more source

No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab. [PDF]

Mult Scler, 2022
Johnsson M, Farman HH, Blennow K, Zetterberg H, Malmeström C, Axelsson M, Lycke J.   +6 more
europepmc   +1 more source

Safety and Efficacy of Extended Interval Dosing for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer During the COVID-19 Pandemic. [PDF]

Clin Lung Cancer, 2022
Hijmering-Kappelle LBM, Hiltermann TJN, Bensch F.   +2 more
europepmc   +1 more source

Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19⁺B-cell repopulation. [PDF]

Mult Scler Relat Disord, 2021
Sahi NK, Abidi SMA, Salim O, Abraham R, Kalra S, Al-Araji A.   +5 more
europepmc   +1 more source

A Pharmacokinetic Analysis of Tobramycin in Patients Less than Five Years of Age with Cystic Fibrosis: Assessment of Target Attainment with Extended-Interval Dosing through Simulation. [PDF]

Antimicrob Agents Chemother, 2022
Downes KJ, Grim A, Shanley L, Rubenstein RC, Zuppa AF, Gastonguay MR.   +5 more
europepmc   +1 more source

Optimizing Rituximab Maintenance Therapy: Outcomes of Extended-Interval Dosing in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. [PDF]

J Clin Med Res
Kittipadakul S, Ongphichetmetha T, Siritho S, Uawithya E, Prayoonwiwat N, Rattanathamsakul N, Jitprapaikulsan J.   +6 more
europepmc   +1 more source

Adoption of Extended-Interval Dosing of Single-Agent Pembrolizumab and Comparative Effectiveness vs Standard Dosing in Time-to-Treatment Discontinuation.

JAMA Oncol, 2022
Strohbehn GW, Holleman R, Burns J, Klamerus ML, Kelley MJ, Kerr EA, Ramnath N, Hofer TP.   +7 more
europepmc   +1 more source

Natalizumab-Associated Progressive Multifocal Leukoencephalopathy After Natalizumab Extended Interval Dosing Therapy in Japan. [PDF]

Neurol Neuroimmunol Neuroinflamm
Takahashi K, Nakahara J, Miura Y, Ae R, Nakamichi K, Harada M, Mori K, Sanjo N, Yukitake M, Yokote H, Hamaguchi T, Yamada M, Takao M.   +12 more
europepmc   +1 more source

Extended-interval dosing of rituximab/ocrelizumab is associated with a reduced decrease in IgG levels in multiple sclerosis. [PDF]

Neurotherapeutics
Rigollet C, Freeman SA, Perriguey M, Stellmann JP, Graille-Avy L, Lafontaine JC, Lemarchant B, Alberto T, Demortière S, Boutiere C, Rico A, Hilézian F, Durozard P, Pelletier J, Maarouf A, Zéphir H, Audoin B.   +16 more
europepmc   +1 more source